Tablets of Truvada, a tenofovir/emtricitabine combination used for HIV<unk> <unk>  (PrEP) is the use of medications used to prevent the spread of disease in people who have not yet been exposed to a disease-causing agent, usually a virus. The term typically refers to the specific use of antiviral drugs as a strategy for HIV/AIDS prevention. PrEP is one of a number of HIV prevention strategies for people who are HIV negative but who also have a higher risk of acquiring HIV, including sexually active adults at increased risk of HIV, people who engage in injection drug use (see drug injection), and serodiscordant sexually active couples. When used as directed, PrEP has been shown to be highly effective, reducing the risk of acquiring HIV up to 99%. , the World Health Organization (WHO) recommends two drug combinations for the use as PrEP for HIV/AIDS: the combination of tenofovir disoproxil and emtricitabine (Truvada), or the combination of tenofovir disoproxil and lamivudine (Cimduo). In October 2019, the U.S. Food and Drug Administration (FDA) approved the combination of emtricitabine and tenofovir alafenamide (Descovy) to be used as PrEP in addition to Truvada, which provides similar levels of protection. In December 2021, the FDA approved cabotegravir (Apretude), which is an injectable form of PrEP. Regulators believe it will improve medication adherence because it only has to be taken once every two months, and widen adoption because it eliminates the need to hide pills or pharmacy visits for discretion.
Pre-exposure prophylaxis
Post-exposure prophylaxis
Transmission-based precautions
Protective isolation
Vaccine storage
Vaccine therapy
Pulse vaccination strategy
Vaccine bundling